5,0
6 nov 2024
Ex dipendente, meno di un anno
Zürich, Zürich
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Nice colleagues, good culture, innovative environment
Svantaggi
The company does not grow as fast as expected due to pharma restructurations in 2024.